That $95M Merck gamble to acquire cCAM? It didn’t pay off.
When Merck $MRK acquired cCAM Biotherapeutics in Israel in the summer of 2015, R&D chief Roger Perlmutter and his crew were intrigued by the potential …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
